Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • INM-900 Series for Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • INM-900 Series for Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

Articles and Videos

Loading...
November 21, 2022
Tribe Webinar: Exploring the Neuroprotective Qualities of Rare Cannabinoids
InMed's President and CEO, Eric A. Adams, and Senior VP, Preclinical Research and Development, Dr. Eric Hsu, talks about "Exploring the Neuroprotective Qualities of Rare...
Source: Tribe Public
Read More
July 29, 2022
Epidermolysis Bullosa News: INM-755 Found Safe in 5 Adults With EB, Trial Opens to Adolescents
Epidermolysis Bullosa News writes about InMed's Phase 2 clinical trial of INM-755 cannabinol cream, an investigational new treatment for epidermolysis bullosa. Excerpt:  INM-755 was found to...
Read More
July 5, 2022
The Dales Report – InMed Pharmaceuticals Unveils Industry Leading Portfolio
Jerry P. Griffin, VP of Sales and Marketing at BayMedica, InMed's subsidiary, is interviewed by Shadd Dales of the The Dales Report to talk about...
Source: The Dales Report
Read More
July 4, 2022
Pharma Tech Outlook: InMed Introduces THCV Into the Health and Wellness Industry
InMed's THCV will bring ample opportunity to the health sector to scale up in the market. Read full story via Pharma Tech Outlook.
Read More
July 3, 2022
What are cannabinoid analogs?
Cannabinoid analogs are novel cannabinoid compounds that are slightly modified from the naturally occurring cannabinoids in the plant. Since they have a new molecular structure...
Read More
June 29, 2022
The Intersection Between Medical and Health & Wellness: Force For Knowledge Cannabis Symposium Panel Discussion
InMed Pharmaceuticals' Dr. Shane Johnson and Radicle Science’s Dr. Jeff Chen join the Force Family Office's Force For Knowledge Cannabis Symposium: The Intersection Between Medical...
Source: Force Family Office
Read More
« Previous 1 2 3 4 5 6 … 18 Next »

Novel Cannabinoid Analogs

Our patentable cannabinoid analogs can be slightly modified to target specific pharmacological properties.
Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • INM-900 Series for Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*